Pardoprunox (INN) (code name SLV-308) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.[1] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.